Skip to content

Kura Oncology KURA Other long-term liabilities

Other long-term liabilities at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's other long-term liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's other long-term liabilities?
Kura Oncology (KURA) reported other long-term liabilities of $204K in Q1 2026.
How has Kura Oncology's other long-term liabilities changed year-over-year?
Kura Oncology's other long-term liabilities decreased by 21.2% year-over-year, from $259K to $204K.
What is the long-term trend for Kura Oncology's other long-term liabilities?
Over 2 years (2023 to 2025), Kura Oncology's other long-term liabilities has grown at a 175.9% compound annual growth rate (CAGR), from $137K to $1.04M.